Yeqiong Xu
Yeqiong Xu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Bangshun He
Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
1 shared publication - Huiling Sun
General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
1 shared publication - Junshan Zhou
Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
1 shared publication Li-Qing Qiu
Laboratory Medicine, Dehua County Hospital, Quanzhou, China
1 shared publication- Lin Zhu
Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
1 shared publication - Ling Gu
College of Traditional Chinese Medicine & College of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China
1 shared publication
Latest Publications
- Open Access
- 28 November 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (12) , 2729
Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases
Cardiovascular disease (CVD) and ischemic stroke (IS) are the primary causes of mortality worldwide. Hypercholesterolemia has been recognized as an independent risk factor for CVD and IS. Numerous clinical trials have unequivocally demonstrated that reducing levels of low-density lipoprotein cholesterol (LDL-C) significantly mitigates the risk of both cardiac and cerebral vascular events, thereby enhancing patient prognosis. Consequently, LDL-C reduction remains a pivotal therapeutic strategy for CVD and IS. However, despite intensive statin therapy, a significant proportion of high-risk hypercholesterolemic patients fail to achieve sufficient reductions in LDL-C levels. In response to this challenge, an inhibitor targeting proprotein convertase subtilisin-kexin type 9 (PCSK9) has been developed as a therapeutic intervention for hyperlipidemia. Numerous randomized controlled trials (RCTs) have conclusively demonstrated that the combination of PCSK9 inhibitors and statins significantly enhances prognosis not only in patients with CVD, but also in those afflicted with symptomatic intracranial artery stenosis (sICAS). PCSK9 inhibitors significantly reduce LDL-C levels by binding to the PCSK9 molecule and preventing its interaction with LDLRs. This prevents degradation of the receptor and increases uptake of LDL-C, thereby decreasing its concentration in blood. Besides significantly reducing LDL-C levels, PCSK9 inhibitors also demonstrate anti-inflammatory and anti-atherosclerotic properties while promoting plaque stabilization and inhibiting platelet aggregation and thrombosis. This article aims to provide a comprehensive review based on the relevant literature regarding the evolving understanding of pleiotropic effects associated with PCSK9 inhibitors, particularly focusing on their impact on the cardiovascular system and central nervous system.
- 28 November 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (12) , 2729
Open AccessPleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases
Cardiovascular disease (CVD) and ischemic stroke (IS) are the primary causes of mortality worldwide. Hypercholesterolemia has been recognized as an independent risk factor for CVD and IS. Numerous clinical trials have unequivocally demonstrated that reducing levels of low-density lipoprotein cholesterol (LDL-C) significantly mitigates the risk of both cardiac and cerebral vascular events, thereby enhancing patient prognosis. Consequently, LDL-C reduction remains a pivotal therapeutic strategy for CVD and IS. However, despite intensive statin therapy, a significant proportion of high-risk hypercholesterolemic patients fail to achieve sufficient reductions in LDL-C levels. In response to this challenge, an inhibitor targeting proprotein convertase subtilisin-kexin type 9 (PCSK9) has been developed as a therapeutic intervention for hyperlipidemia. Numerous randomized controlled trials (RCTs) have conclusively demonstrated that the combination of PCSK9 inhibitors and statins significantly enhances prognosis not only in patients with CVD, but also in those afflicted with symptomatic intracranial artery stenosis (sICAS). PCSK9 inhibitors significantly reduce LDL-C levels by binding to the PCSK9 molecule and preventing its interaction with LDLRs. This prevents degradation of the receptor and increases uptake of LDL-C, thereby decreasing its concentration in blood. Besides significantly reducing LDL-C levels, PCSK9 inhibitors also demonstrate anti-inflammatory and anti-atherosclerotic properties while promoting plaque stabilization and inhibiting platelet aggregation and thrombosis. This article aims to provide a comprehensive review based on the relevant literature regarding the evolving understanding of pleiotropic effects associated with PCSK9 inhibitors, particularly focusing on their impact on the cardiovascular system and central nervous system.
- 1 March 2016
- Published by Elsevier in Journal of Surgical Research
- Vol. 201 (1) , 188-195
Prognostic value of ABO blood group in patients with gastric cancer
- 1 March 2016
- Published by Elsevier in Journal of Surgical Research
- Vol. 201 (1) , 188-195
Prognostic value of ABO blood group in patients with gastric cancer
- Open Access
- 12 July 2011
- Published by Springer Nature in BMC Medical Genetics
- Vol. 12 (1) , 94
Effects of genetic variations in the Adiponectin pathway genes on the risk of colorectal cancer in the Chinese population
Background: Decreased expression of adiponectin (ADIPOQ) is associated with an increased risk for developing colorectal cancer (CRC) in humans. This study was designed to determine whether polymorphisms present in theADIPOQand its type 1 receptor (ADIPOR1) could affect the risk of CRC.Methods: We measured five polymorphisms in theADIPOQand two polymorphisms inADIPOR1, and analyzed their associations with CRC risk in 420 CRC patients and 555 age- and gender-matched healthy individuals.Results: Multivariate logistic regression analyses revealed that the CRC risks (adjusted odds ratio and 95% confidence interval) associated with theADIPOR1genotypes were 0.53 (95% CI, 0.35-0.81) for rs12733285C/T, 0.59 (95% CI, 0.45-0.78) for rs1342387A/G, and 0.59 (95% CI, 0.39-0.89) for rs1342387A/A, respectively. Furthermore, the risks were more significant in carriers of the allele A of rs1342387A/G (adjusted OR, 0.59; 95% CI, 0.46-0.77) than noncarriers (G/G). In a further subgroup analysis, we observed that rs266729G/C was associated with an increased risk for colon cancer (adjusted OR, 1.50; 95% CI, 1.05-2.14) but not for rectal cancer (adjusted OR, 0.88; 95% CI, 0.63-1.22), and that carriers of the G allele had an increased risk for developing colon cancer (adjusted OR, 1.45; 95% CI, 1.03-2.05).Conclusions: We conclude that the rs12733285C/T genotype and the carriage of the A allele of rs1342387 (A/G or A/A) inADIPOR1are the protective factors for CRC, while that rs266729G/C and G allele ofADIPOQare the risk factors for colon cancer after excluding rectal cancer cases.
- 12 July 2011
- Published by Springer Nature in BMC Medical Genetics
- Vol. 12 (1) , 94
Open AccessEffects of genetic variations in the Adiponectin pathway genes on the risk of colorectal cancer in the Chinese population
Background: Decreased expression of adiponectin (ADIPOQ) is associated with an increased risk for developing colorectal cancer (CRC) in humans. This study was designed to determine whether polymorphisms present in theADIPOQand its type 1 receptor (ADIPOR1) could affect the risk of CRC.Methods: We measured five polymorphisms in theADIPOQand two polymorphisms inADIPOR1, and analyzed their associations with CRC risk in 420 CRC patients and 555 age- and gender-matched healthy individuals.Results: Multivariate logistic regression analyses revealed that the CRC risks (adjusted odds ratio and 95% confidence interval) associated with theADIPOR1genotypes were 0.53 (95% CI, 0.35-0.81) for rs12733285C/T, 0.59 (95% CI, 0.45-0.78) for rs1342387A/G, and 0.59 (95% CI, 0.39-0.89) for rs1342387A/A, respectively. Furthermore, the risks were more significant in carriers of the allele A of rs1342387A/G (adjusted OR, 0.59; 95% CI, 0.46-0.77) than noncarriers (G/G). In a further subgroup analysis, we observed that rs266729G/C was associated with an increased risk for colon cancer (adjusted OR, 1.50; 95% CI, 1.05-2.14) but not for rectal cancer (adjusted OR, 0.88; 95% CI, 0.63-1.22), and that carriers of the G allele had an increased risk for developing colon cancer (adjusted OR, 1.45; 95% CI, 1.03-2.05).Conclusions: We conclude that the rs12733285C/T genotype and the carriage of the A allele of rs1342387 (A/G or A/A) inADIPOR1are the protective factors for CRC, while that rs266729G/C and G allele ofADIPOQare the risk factors for colon cancer after excluding rectal cancer cases.